New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLarazotide Acetate vs Cerebrolysin

Larazotide Acetate vs Cerebrolysin

Side-by-side comparison of key properties, dosing, and research.

Recovery & Repair
Larazotide Acetate
Cognitive EnhancementAnti-Aging & Longevity
Cerebrolysin
Summary
Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
Half-Life
Local gut action; minimal systemic exposure
Variable for the complex; individual peptide fractions: minutes to hours
Admin Route
Oral
IV, IM
Research
Typical Dose
0.5-2 mg
5–10 mL
Frequency
3x daily
Daily for 10–20 days
Key Benefits
  • Directly reduces intestinal tight junction permeability
  • Clinical efficacy in celiac disease (Phase 3 trials)
  • Reduces systemic inflammation from gut permeability
  • Targets root cause of leaky gut (Zonulin pathway)
  • Local gut action without systemic absorption
  • Potential application in IBS, IBD, autoimmune conditions
  • Promotes neurogenesis and synaptic plasticity
  • Approved for stroke rehabilitation (accelerates recovery)
  • Alzheimer's disease: slows progression and improves cognition
  • Traumatic brain injury recovery
  • Enhances memory and executive function
  • Neuroprotection against oxidative stress and excitotoxicity
  • Anti-amyloid and anti-tau effects
  • Mood improvement and reduced anxiety
Side Effects
  • Headache (mild, dose-dependent)
  • Nausea (rare)
  • Well-tolerated overall in clinical trials
  • Generally well tolerated
  • Mild nausea and dizziness (IV infusion)
  • Headache at initiation
  • Rare: agitation (usually at very high doses)
  • +2 more
Stacks With